Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

European Haematology Association

Bristol-Myers Squibb (BMS) building

BMS buys into gene therapy with $1bn uniQure alliance

US firm on a deal spree in 2015 as it racks up yet another collaboration

- PMLiVE

Humira gets OK for childhood psoriasis in Europe

First biologic drug to be approved in the region for children as young as four

- PMLiVE

PD-1 cancer market overrated, says new report

The immuno-oncology market for new oncology drugs may be worth half of current expectations

- PMLiVE

Amgen gets quick US review for Kyprolis

To be considered as a second-line therapy for multiple myeloma

- PMLiVE

AbbVie: New firm, new thinking

UK general manager Matt Regan talks to PME about creating an evolved culture from Abbott

- PMLiVE

Novo Nordisk sheds autoimmune portfolio to BMS

Continues the trend of pharma buying up unwanted assets from rival firms

- PMLiVE

The end of hepatitis C?

Next-gen hep C therapies may see the disease's global elimination - but treament access must be stepped up dramatically

- PMLiVE

AstraZeneca bullish on diabetes franchise fortunes

Other big pharma firms face a difficult 2015, but AZ is confident it won't

Bristol-Myers Squibb (BMS) building

Opdivo gains new US lung cancer licence

Adds to Bristol-Myers Squibb’s therapeutic vaccine’s melanoma indication

- PMLiVE

AbbVie to acquire cancer biopharma Pharmacyclics for $21bn

Comes six months after the US firm pulled out of a $54bn deal with Shire

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

- PMLiVE

NICE issues fresh rejection for Celgene’s cancer drug Imnovid

Drugpricing watchdog says the treatment is too costly for NHS use

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links